Spero therapeutics to provide business update and report fourth quarter and full year 2023 financial results on wednesday, march 13, 2024

Cambridge, mass., march 06, 2024 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (mdr) bacterial infections, today announced that it will host a conference call and live audio webcast on wednesday, march 13, 2024 at 4:30 p.m. et to report its fourth quarter and full year financial results and provide an update on its business and pipeline.
SPRO Ratings Summary
SPRO Quant Ranking